Phase 2 N=20 Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
Bladder Cancer
Primary: EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib — -0.29; 0.128 fold change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,087 Prevenar (13v) Infant Drug Use Investigation
Infants
Primary: Number of Participants With Adverse Reactions — 432; 3 Participants
N/A N=105 Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses
Visual Disorders
Primary: Proportion of Eyes Grade 3 or Higher SLF — 0; 0 Proporiton of Subject Eyes
N/A N=123 Observational Study With PASCALLERG ® in Patients With Hay Fever
Hay Fever
Primary: Efficacy of Pascallerg — 60; 44; 15; 2 participants
N/A N=965 Real World Expanded Multicenter Study of the MitraClip® System (REALISM)
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Number of Participants With Major Adverse Events — 5; 3; 98; 31 Participants
N/A N=76 Evaluating Air Leak Detection in Intubated Patients
Critical Care
Primary: CO2 Leakage Above the ETT Cuff, Measured Over Time. — 0.09; 0.22 [CO2 mmHg*hour]/hour
Phase 2 N=158 Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study
Rheumatoid Arthritis
Primary: American College of Rheumatology (ACR) 20 Response Rate at Week 2 — 45.0; 43.2; 46.2; 47.4 percentage of participants
N/A N=54 2-week Evaluation of Marketed Silicone Hydrogel Contact Lenses in Indian Population
Visual Acuity
Primary: Subjective Overall Comfort — 58.65; 59.44 units on a scale
Phase 3 N=150 A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events — 91.3 percentage of participants
N/A N=16 Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
Persistent Depressive Disorder
Primary: Paid Work Hours at Week 12 — 30.3 hours — p=0.005
N/A N=34 Cognitive Training and Dual-task Ability
Gait Disorder
Primary: Change Scores in Timed up and go With Cognitive Task — -0.89; -0.37; -0.64; -1.42 seconds — p=0.562
Phase 2 N=32 SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
Familial Amyotrophic Lateral Sclerosis
Primary: Mean Change in SOD1 CSF — 6.8 ng/ml
N/A N=106 Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease
Crohn's Disease
Primary: Work Productivity and Activity Index (WPAI): Absenteeism — 38.3; 14.2 units on a scale — p==0.004
N/A N=202 Shared Decision-Making for Elderly Depressed Primary Care Patients
Depression
Primary: Number of Participants Who Adhered to Physician Recommended Treatment — 40; 16 Participants
N/A N=22 Enhancing Emotion Regulation During Driving in OEF/OIF Veterans
Driving Distress Secondary to Trauma During Deployment
Primary: Reduced Heart Rate During Driving (Aggregated Over Sessions) — 3.21; 9.0 beats per minute